Literature DB >> 18511929

Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time.

Keith A Wafford1, Bjarke Ebert.   

Abstract

Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep-wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511929     DOI: 10.1038/nrd2464

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  22 in total

1.  Effects of GF-015535-00, a novel α1 GABA A receptor ligand, on the sleep-wake cycle in mice, with reference to zolpidem.

Authors:  Christelle Anaclet; Mei Zhang; Chunmei Zhao; Colette Buda; Laurent Seugnet; Jian-Sheng Lin
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

2.  Contribution of GABA(A) receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys.

Authors:  Bradford D Fischer; John R Atack; Donna M Platt; David S Reynolds; Gerard R Dawson; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2010-12-30       Impact factor: 4.530

3.  Benzodiazepine-site pharmacology on GABAA receptors in histaminergic neurons.

Authors:  A C May; W Fleischer; O Kletke; H L Haas; O A Sergeeva
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

4.  Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.

Authors:  Michel A Steiner; Hugues Lecourt; Daniel S Strasser; Catherine Brisbare-Roch; François Jenck
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

5.  Neurophysiological signature of gamma-hydroxybutyrate augmented sleep in male healthy volunteers may reflect biomimetic sleep enhancement: a randomized controlled trial.

Authors:  Dario A Dornbierer; Diego M Baur; Benjamin Stucky; Boris B Quednow; Thomas Kraemer; Erich Seifritz; Oliver G Bosch; Hans-Peter Landolt
Journal:  Neuropsychopharmacology       Date:  2019-04-08       Impact factor: 7.853

6.  Human locus coeruleus neurons express the GABA(A) receptor gamma2 subunit gene and produce benzodiazepine binding.

Authors:  Kati S Hellsten; Saku T Sinkkonen; Thomas M Hyde; Joel E Kleinman; Terttu Särkioja; Anu Maksimow; Mikko Uusi-Oukari; Esa R Korpi
Journal:  Neurosci Lett       Date:  2010-04-22       Impact factor: 3.046

Review 7.  Good night and good luck: norepinephrine in sleep pharmacology.

Authors:  Heather A Mitchell; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2009-10-13       Impact factor: 5.858

8.  Rescue of deficient amygdala tonic γ-aminobutyric acidergic currents in the Fmr-/y mouse model of fragile X syndrome by a novel γ-aminobutyric acid type A receptor-positive allosteric modulator.

Authors:  Brandon S Martin; Gabriel Martinez-Botella; Carlos M Loya; Francesco G Salituro; Albert J Robichaud; Molly M Huntsman; Mike A Ackley; James J Doherty; Joshua G Corbin
Journal:  J Neurosci Res       Date:  2015-08-26       Impact factor: 4.164

9.  Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study.

Authors:  Oluwaseun Akeju; Lauren E Hobbs; Lei Gao; Sara M Burns; Kara J Pavone; George S Plummer; Elisa C Walsh; Tim T Houle; Seong-Eun Kim; Matt T Bianchi; Jeffrey M Ellenbogen; Emery N Brown
Journal:  Clin Neurophysiol       Date:  2017-10-20       Impact factor: 3.708

10.  Inhibition of thalamic excitability by 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridine-3-ol: a selective role for delta-GABA(A) receptors.

Authors:  Murray B Herd; Nicola Foister; Dev Chandra; Dianne R Peden; Gregg E Homanics; Verity J Brown; David J K Balfour; Jeremy J Lambert; Delia Belelli
Journal:  Eur J Neurosci       Date:  2009-03       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.